Table 4.

Studies on the Application of Other Treatment Methods Targeting PSMA in the Treatment of PCa

Interventions	Type of Study	Objectives	Number of Studies and/or Patients	Results	References
Targeting PSMA docetaxel nanoparticles (BIND-014)	Prospective single-group clinical trial	This study investigated the safety and efficacy of BIND-014 in the treatment of mCRPC.	42 patients	BIND-014 treatment is effective and well tolerated in mCRPC patients who have not received chemotherapy.	Autio KA et al, 2018105
PSMA ADC	Prospective single-group clinical trial	This study evaluated the safety and initial antitumor effects of the PSMA ADC in patients with refractory PCa.	52 patients	PSMA ADC showed acceptable toxicity in an extensively pretreated mCRPC population. Antitumor activity was observed at doses over and including 2.5 mg/kg.	Petrylak DP et al, 2019106
PSMA ADC	Prospective single-group clinical trial	This study investigated the tumor killing activity of PSMA ADC against PCa.	119 patients	PSMA ADC showed certain tumor killing activity of PCa through PSA reduction and TC reduction.	Petrylak DP et al, 2020107
A humanized monoclonal antibody targeting PSMA (MLN2704)	Prospective non-randomized controlled study	This study evaluated the dose-limiting toxicity and maximum tolerated dose of MLN2704.	62 patients	MLN2704 has limited activity in metastatic castration-resistant PCa.	Milowsky MI et al, 2016108